|
市場調查報告書
2007年第4季的藥價、補貼、處方動向
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007
|
2007年第4季的藥價、補貼、處方動向 是由出版商Decision Resources, Inc.在2008年01月所出版的。
這份英文市場調查報告書包含30 Pages 價格從美金2250起跳。
本報告書內容包括：2007年第4季主要藥品市場的藥價、補貼、處方動向概要、美國、歐洲各國、日本的動向、未來預測等。內容綱要摘記如下：
實施概要
概要
美國
- Medicare補貼減少及針對兒童的基本健康保險延期等暫時對策
- 藥品進口減少
- Medicare的實行壓力
- PBM改善透明度的承諾
- 因為通膨因素的Medicaid貼現要求
- 減免非專利藥品及針對慢性病治療的患者自我負擔額度
- 全民保險的發展
- 65歲的補助減少
歐洲
法國
- 法國的健康保險制度
- 社會保險預算增加藥品產業的壓力
- 針對慢性疾病治療的保險適用改革
德國
- 2007年的市場動向
- 2008年的藥品預算
- 採用新的參考藥價類群
- 健康經濟評估程序相關討論
- 貼現契約增加
義大利
西班牙
英國
- 針對技術評估之NICE方法的修正案
- 針對對藥局直接銷售的OFT報告書
- 蘇格蘭廢除照處方價格請款的制度
日本
- 2008年的藥價及補貼制度修正
- 為刺激非專利藥品的處方模式變化
藥品產業的未來預測及影響
Abstract
Introduction
The fourth quarter of 2007 was fairly quiet in the pricing and reimbursement
arena. In the United States, the presidential election, legislation in
California, and a new initiative from health plans focused attention on the
uninsured and universal coverage. A public consultation on the future of
pharmaceuticals highlighted the challenges confronting drug manufacturers in
Europe, while the Japanese government seemingly changed course on overhauling
its pharmaceutical pricing and reimbursement system.
Get the Answers You Need to Shape Your Strategy
- Pending U.S. legislation would allow the Department of Health and Human
Services to create a national Medicare formulary. How would HHS use this
formulary in its price negotiations with pharmaceutical manufacturers?
- U.S. employers and health plans are recognizing the fi nancial and health
benefi ts of promoting greater use of generic drugs and improved adherence to
chronic disease therapy. What strategies are they pursuing in their efforts
to improve patient adherence with chronic disease therapy and encourage the
use of generics?
- Pressure to tackle the growth in the ranks of uninsured U.S. residents is
mounting. Which states have enacted their own universal coverage
legislation? How will the presidential election affect this issue at the
national level?
Scope
- Overview: major events in the fourth quarter of 2007 in the pricing,
reimbursement, and prescribing environment in the major pharmaceutical markets
under study.
- United States: leading stories in 2007, including SCHIP, decline in drug
imports, copayment reductions and waivers for generics and chronic disease
therapies, and many others.
- European Union: responses to public consultation on the future of
pharmaceuticals in Europe.
- France: pressures on pharmaceutical industry, potential reforms for
chronic disease treatments.
- Germany: new reference pricing groups, health economic evaluation, growth
in rebate contracts.
- Italy: market trends in 2007.
- Spain: amendments to the reference pricing system.
- United Kingdom: proposed amendments to NICE' s methods for technology
appraisals, OFT report on direct-to-pharmacy distribution, abolition of
prescription charges in Scotland.
- Japan: delay in overhaul of pricing and reimbursement system, efforts to
increase use of generics.
- Outlook and implications for the pharmaceutical industry: the outlook for
pharma in the United States, Europe, and Japan.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- United States
- Temporary Measures to Defer Medicare Reimbursement Cuts and Prolong
Basic Health Insurance for Children
- Decline in Drug Imports
- Pressure for the Introduction of a Medicare Formulary
- PBMs Commit to Greater Transparency
- Call for Infl ation-Based Medicaid Rebates
- Copayment Reductions and Waivers for Generics and Chronic Disease
Therapies
- Momentum for Universal Health Insurance
- Benefi t Cuts at Age 65 Judged Acceptable
- European Union
- Responses to Public Consultation on the Future of Pharmaceuticals in
Europe
- France
- French Health Care System at a Crossroads
- Social Security Budget Increases Pressure on Pharmaceutical Industry
- Potential Reform of Coverage of Treatments for Chronic Diseases
- Germany
- Market Trends in 2007
- Pharmaceutical Budget for 2008
- Introduction of New Reference Pricing Groups
- Continuing Debate Over Procedures for Health Economic Evaluation
- Continued Growth in Rebate Contracts
- Italy
- Spain
- Amendments to the Reference Pricing System
- United Kingdom
- Proposed Amendments to NICE' s Methods for Technology Appraisals
- OFT Report on Direct-to-Pharmacy Distribution
- Abolition of Prescription Charges in Scotland
- Japan
- Overhaul of Pricing and Reimbursement System Unlikely in 2008
- Change to Prescription Form to Stimulate Generics Substitution
- Outlook and Implications for the Pharmaceutical Industry
Tables:
- 1. New Reference Pricing Groups Implemented in Germany Effective January
1, 2008
- 2. 2007 Retail Prices and New Reference Prices of Largest Pack Size of
Nebilet
- 3. Proposed Changes to the Hierarchy of National Health Insurance Price
Premiums in Japan
- 4. Revision Rates for Japanese Reimbursement Prices, 1994-2006
Figures:
- 1. Uninsured U.S. Residents, 2002-2006
- 2. Ten Most Common Registered Chronic Diseases in France, 2006
- 3. Annual Sales of Drugs Facing Patent Expiration in Italy in 2008
|
